PortfoliosLab logoPortfoliosLab logo

Highlights

EPS (TTM)
-$1.93
EBITDA (TTM)
-$36.18M
Year Range
$0.25 - $3.69
ROA (TTM)
-377.37%
ROE (TTM)
-2,113.58%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

MDCX Performance Chart

Medicus Pharma Ltd (MDCX) is down 70.7% since the beginning of the year. At $0 per share, MDCX is trading 87.8% below its 52-week high of $4.


Loading charts...

S&P 500 Index

Returns By Period

Medicus Pharma Ltd (MDCX) has returned -70.65% so far this year and -81.97% over the past 12 months.


Medicus Pharma Ltd

1D
-1.86%
1M
49.67%
YTD
-70.65%
6M
-71.22%
1Y
-81.97%
3Y*
5Y*
10Y*

Benchmark (S&P 500 Index)

1D
-0.37%
1M
-0.01%
YTD
9.16%
6M
8.64%
1Y
25.22%
3Y*
19.78%
5Y*
11.99%
10Y*
13.88%
*Multi-year figures are annualized to reflect compound growth (CAGR)

MDCX Monthly Returns History

Based on dividend-adjusted daily data since Nov 14, 2024, MDCX's average daily return is -0.11%, while the average monthly return is -4.11%.

Historically, 45% of months were positive and 55% were negative. The best month was Feb 2025 with a return of +53.5%, while the worst month was Mar 2026 at -70.0%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 3 months.

On a daily basis, MDCX closed higher 46% of trading days. The best single day was Mar 9, 2026 with a return of +34.3%, while the worst single day was Mar 5, 2026 at -50.9%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-22.22%28.57%-70.00%-38.43%34.11%18.47%-70.65%
20257.00%53.46%-6.77%13.01%-39.34%17.25%-17.73%-21.14%19.33%5.40%-9.84%-30.45%-37.04%
2024-13.03%-9.87%-21.61%

Benchmark Metrics

Medicus Pharma Ltd has an annualized alpha of -35.65%, beta of 1.05, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since November 14, 2024.

  • This stock participated in 286.19% of S&P 500 Index downside but only -137.94% of its upside - more exposed to losses than it benefited from rallies.
  • R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-35.65%
Beta
1.05
0.02
Upside Capture
-137.94%
Downside Capture
286.19%

Return for Risk

Risk / Return Rank

MDCX ranks 12 for risk / return — in the bottom 12% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.


MDCX Risk / Return Rank: 1212
Overall Rank
MDCX Sharpe Ratio Rank: 1414
Sharpe Ratio Rank
MDCX Sortino Ratio Rank: 1414
Sortino Ratio Rank
MDCX Omega Ratio Rank: 1414
Omega Ratio Rank
MDCX Calmar Ratio Rank: 77
Calmar Ratio Rank
MDCX Martin Ratio Rank: 99
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Medicus Pharma Ltd (MDCX) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


MDCXBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-2.68

Sortino ratioReturn per unit of downside risk

-3.63

Omega ratioGain probability vs. loss probability

0.88

1.37

-0.48

Calmar ratioReturn relative to maximum drawdown

-0.89

2.78

-3.68

Martin ratioReturn relative to average drawdown

-1.37

12.44

-13.81

Dividends

Dividend History


Medicus Pharma Ltd doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Medicus Pharma Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Medicus Pharma Ltd was 96.47%, occurring on May 5, 2026. The portfolio has not yet recovered.

The current Medicus Pharma Ltd drawdown is 94.23%.


Related event

Drawdown

Fall

Recovery

Underwater

2026 bear market2026
-96.47%May 2026
11mo 20d
1y 1moMay 2025 - now
2025 selloff2025
-42.26%Mar 2025
11d1mo 29d
2mo 10dFeb 2025 - May 2025
2024 bear market2024
-38.06%Nov 2024
8d2mo 24d
3mo 2dNov 2024 - Feb 2025
2025 selloff2025
-5.93%Feb 2025
3d3d
6dFeb 2025 - Feb 2025
2025 selloff2025
-5.85%May 2025
0s1d
1dMay 2025 - May 2025

Drawdown Indicators


MDCXBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-96.47%

-56.78%

-39.69%

Max Drawdown (1Y)

Largest decline over 1 year

-91.91%

-9.10%

-82.81%

Max Drawdown (3Y)

Largest decline over 3 years

-18.90%

Max Drawdown (5Y)

Largest decline over 5 years

-25.43%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

-94.23%

-1.80%

-92.43%

Average Drawdown

Average peak-to-trough decline

-57.66%

-10.71%

-46.95%

Ulcer Index

Depth and duration of drawdowns from previous peaks

59.85%

2.03%

+57.82%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Medicus Pharma Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Medicus Pharma Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with MDCX

Add Medicus Pharma Ltd to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with MDCX